Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
1 Apr 24
8-K
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
28 Mar 24
S-3ASR
Automatic shelf registration
7 Mar 24
RW
Registration withdrawal request
7 Mar 24
S-8
Registration of securities for employees
6 Mar 24
S-3
Shelf registration
6 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
6 Mar 24
8-K
Departure of Directors or Certain Officers
22 Feb 24
8-K
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
8 Feb 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
8-K
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
4 Jan 24
D
$50.00 mm in equity / options / securities to be acquired, sold $50.00 mm, 2 investors
3 Jan 24
8-K
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
26 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
8 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results
7 Nov 23
8-K
Termination of a Material Definitive Agreement
2 Nov 23
ARS
2022 FY
Annual report to shareholders
26 Oct 23
DEFA14A
Additional proxy soliciting materials
26 Oct 23
DEF 14A
Definitive proxy
26 Oct 23
8-K
Zymeworks Announces New Director Nominee
16 Oct 23
8-K
Termination of a Material Definitive Agreement
21 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results
10 Aug 23
8-K
Zymeworks Appoints New Director
29 Jun 23
8-A12B/A
Registration of securities on exchange (amended)
12 Jun 23
8-K
Material Modifications to Rights of Security Holders
12 Jun 23
8-K
Other Events
2 Jun 23
8-K
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
18 May 23
8-K
Entry into a Material Definitive Agreement
16 May 23
424B5
Prospectus supplement for primary offering
8 May 23
424B5
Prospectus supplement for primary offering
8 May 23
8-K
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
8 May 23
10-Q
2023 Q1
Quarterly report
8 May 23
EFFECT
Notice of effectiveness
1 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
8-K
Entry into a Material Definitive Agreement
26 Apr 23
8-K
ZW191 demonstrates strong responses in FRα-low expressing patient-derived xenograft (PDX) models with favorable pharmacokinetic and safety profiles
18 Apr 23
8-K
Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors
10 Apr 23
Latest ownership filings
4
Neil Gallagher
2 Apr 24
3
Neil Gallagher
2 Apr 24
3
Scott Platshon
4 Mar 24
SC 13D
EcoR1 Capital, LLC
22 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
4
Alessandra Cesano
9 Feb 24
3
Alessandra Cesano
9 Feb 24
SC 13G/A
MORGAN STANLEY
9 Feb 24
SC 13G
BlackRock Inc.
29 Jan 24
4
Kenneth Galbraith
8 Jan 24
4
Christopher Astle
8 Jan 24
4
Paul Andrew Moore
8 Jan 24
4
Jeffrey T L Smith
8 Jan 24
144
Notice of proposed sale of securities
5 Jan 24
144
Notice of proposed sale of securities
5 Jan 24
144
Notice of proposed sale of securities
5 Jan 24
3
Jeffrey T L Smith
5 Jan 24
4
Change in insider ownership
28 Dec 23
4
Christopher Astle
11 Dec 23
4
Carlos Campoy
8 Dec 23
4
HOLLINGS RENTON
8 Dec 23
4
Kelvin Neu
8 Dec 23
4
Troy Cox
8 Dec 23
4
Susan Mahony
8 Dec 23
4
Derek John Michael Miller
8 Dec 23
4
Nancy Davidson
8 Dec 23
4
Kenneth J. Hillan
8 Dec 23
3
Nancy Davidson
8 Dec 23
4
Carlos Campoy
30 Jun 23
3
Carlos Campoy
30 Jun 23
SC 13G/A
EcoR1 Capital, LLC
21 Jun 23
4
Change in insider ownership
21 Jun 23
4
Derek John Michael Miller
10 Apr 23
3
Derek John Michael Miller
10 Apr 23
4
Change in insider ownership
30 Mar 23
4
Neil A Klompas
14 Mar 23
SC 13G/A
Redmile Group, LLC
14 Feb 23